The company has received final approvals from the United States Food and Drug Administration (USFDA) for its Deferasirox tablets in the strengths of 90 mg and 360 mg and Deferasirox tablets for oral suspension in the strengths of 125 mg, 250 mg, and 500 mg, Alembic Pharmaceuticals said in a regulatory filing.Alembic Pharma gets USFDA nod for generic chronic iron overload treatment tablets
The company has received final approvals from the United States Food and Drug Administration (USFDA) for its Deferasirox tablets in the strengths of 90 mg and 360 mg and Deferasirox tablets for oral suspension in the strengths of 125 mg, 250 mg, and 500 mg, Alembic Pharmaceuticals said in a regulatory filing.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment